A new study confirms that 8 weeks of ledipasvir/sofosbuvir (Harvoni) treatment of hepatitis C virus (HCV) genotype 1 (GT1) infection without cirrhosis is as effective as 12 weeks in patients of different races and ethnicity, and challenges guidelines that recommend the shorter regimen for non-black patients.
Julia Marcus, PhD, MPH, Assistant Professor, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, and colleagues contrast their findings to a guideline which they charge is based on “limited evidence and could exacerbate observed racial/ethnic disparities in HCV treatment initiation.”
